Paper Details

  1. Home
  2. Paper Details

Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.

Author: AlvarezHortensia, DomingoPere, GenebatMiguel, GuardiolaJosé M, Hernández-QueroJosé, LealManuel, LluchJosé F, MariñoAna, MartínezLorena, Martínez-MadridOnofre, Martínez-PérezMaría A, MarínJorge, Ruiz-MateosEzequiel, Sánchez-VillegasJorge, VeraFrancisco, de la LlanaFrancisco García

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Telaprevir-based triple therapy for genotype 1 hepatitis C in HIV-coinfected patients with cirrhosis showed a 71.9% success rate after 24 weeks. However, 15.6% of patients experienced treatment failure due to side effects.
Paper Details　
Original Abstract of the Article :
Efficacy and tolerability of telaprevir, pegylated interferon and ribavirin combination was assessed in 32 cirrhotic genotype 1 hepatitis C (HCV)-HIV coinfected patients. Undetectability of HCV-RNA was observed in 23/32 (71.9%) patients after 24 weeks. Treatment failure was observed in 9/32 subjects...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.antiviral.2014.01.019

データ提供：米国国立医学図書館（NLM）

Telaprevir: A Potential Oasis in the Desert of HIV-HCV Coinfection

HIV-HCV coinfection, a complex and challenging condition, is like a double desert storm, requiring careful navigation and effective treatment. This study investigates the efficacy and tolerability of telaprevir, a protease inhibitor used in the treatment of hepatitis C, in cirrhotic patients with HIV-HCV coinfection.

Navigating the Complexities of HIV-HCV Coinfection: A Multifaceted Approach

The study found that telaprevir, combined with pegylated interferon and ribavirin, achieved undetectable HCV-RNA levels in a significant proportion of patients after 24 weeks of treatment. However, the study also highlighted the potential for drug-related side effects, requiring close monitoring. This is like a caravan encountering both treacherous terrain and unexpected weather patterns, demanding flexibility and adaptability to overcome the challenges. The study highlights the need for careful patient selection and ongoing monitoring to maximize the benefits of telaprevir treatment.

Finding Hope in the Desert of Coinfection: A Promising New Approach

This study provides valuable insights into the potential of telaprevir-based triple therapy for treating HCV in cirrhotic HIV-coinfected patients, offering a glimmer of hope in a challenging landscape. It emphasizes the importance of careful patient selection and vigilant monitoring to ensure optimal treatment outcomes. This is like a caravan leader choosing the right camels for a demanding journey, ensuring their success by carefully considering their strengths and limitations.

Dr. Camel's Conclusion

HIV-HCV coinfection is a complex and challenging desert, but research continues to offer new paths to treatment. This study highlights the potential of telaprevir-based triple therapy, offering a promising oasis in a dry and unforgiving landscape. It's important to remember that every journey is different, and finding the right approach for each individual is key to navigating this complex terrain.

Date :
  1. Date Completed 2014-11-04
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

24491797

DOI: Digital Object Identifier

10.1016/j.antiviral.2014.01.019

Related Literature

Article Analysis
・Side Effects of telaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.